Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study
暂无分享,去创建一个
D. Goff | W. Cushman | W. Ambrosius | J. Bigger | E. Chew | H. Gerstein | J. Lovato | R. Danis | C. Greven | L. Perdue | F. Ismail-Beigi | S. Genuth | M. Elam | H. Ginsberg | Letitia H. Perdue | M. Davis
[1] W. Cushman,et al. Nine-Year Effects of 3.7 Years of Intensive Glycemic Control on Cardiovascular Outcomes , 2016, Diabetes Care.
[2] L. Aiello,et al. Intensive diabetes therapy and ocular surgery in type 1 diabetes. , 2015, The New England journal of medicine.
[3] Walter T Ambrosius,et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. , 2014, Ophthalmology.
[4] R. Frank. Systemic therapies for diabetic retinopathy: the accord eye study. , 2014, Ophthalmology.
[5] N. White,et al. Effect of Intensive Diabetes Therapy on the Progression of Diabetic Retinopathy in Patients With Type 1 Diabetes: 18 Years of Follow-up in the DCCT/EDIC , 2014, Diabetes.
[6] P. Mitchell,et al. Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives. , 2013, Current medicinal chemistry.
[7] P. Mitchell,et al. Fenofibrate - a potential systemic treatment for diabetic retinopathy? , 2012, American journal of ophthalmology.
[8] R. Garrick. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[9] Rodica Pop-Busui,et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.
[10] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.
[11] Lukasz Januszkiewicz. [The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus]. , 2010, Kardiologia polska.
[12] John B Buse,et al. Effects of combination lipid therapy in type 2 diabetes mellitus. , 2010, The New England journal of medicine.
[13] Kevin A Peterson,et al. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus , 2011 .
[14] Michael E. Miller,et al. ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .
[15] S. Schinner,et al. Effects of Intensive Glucose Lowering in Type 2 Diabetes , 2009 .
[16] R. Holman,et al. 10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.
[17] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[18] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.
[19] D. Goff,et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. , 2007, The American journal of cardiology.
[20] W. Ambrosius,et al. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). , 2007, The American journal of cardiology.
[21] UK Prospective Diabetes Study Group. UK prospective diabetes study (UKPDS) , 2004, Diabetologia.
[22] Matthew D. Davis,et al. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. , 2000, The New England journal of medicine.
[23] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[24] R. Holman,et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .
[25] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[26] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[27] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[28] F. Ferris,et al. How effective are treatments for diabetic retinopathy? , 1993, JAMA.
[29] Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.
[30] S. Colagiuri,et al. The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.